Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 12/20 | 0.57 |
| ▸ | KIT | P10721 | 4/20 | 0.53 |
| ▸ | FLT3 | P36888 | 4/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL740704 | 0.88 | AURKA (0.56) | AURKAKITFLT3NTRK1FGFR1 | |
| SCHEMBL3819108 | 0.87 | AURKA (0.61) | AURKAKITFLT3NTRK1FGFR1 | |
| SCHEMBL741230 | 0.87 | AURKA (0.59) | AURKAKITFLT3NTRK1FGFR1 | |
| Hydrochloric Acid SCHEMBL740993 | 0.86 | AURKA (0.58) | AURKAKITFLT3NTRK1FGFR1 | |
| SCHEMBL2417414 | 0.83 | AURKA (0.65) | AURKAKITFLT3NTRK1KDR | |
| SCHEMBL13685830 | 0.82 | AURKA (0.54) | AURKAKITFLT3NTRK1FGFR1 | |
| SCHEMBL3817811 | 0.82 | AURKA (0.57) | AURKAKITFLT3NTRK1FGFR1 | |
| SCHEMBL2418296 | 0.82 | AURKA (0.76) | AURKAKITFLT3KDR | |
| SCHEMBL3816332 | 0.81 | AURKA (0.56) | AURKAKITFLT3 | |
| SCHEMBL2416867 | 0.81 | AURKA (0.61) | AURKAKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595320-B2 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| US-20080146542-A1 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146542-A1 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CASP3 | AURKA 519/4885KIT 138/4885FLT3 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.